STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRMD
  4. [8-K] CorMedix Inc. Reports Material Event

CorMedix (NASDAQ: CRMD) replaces CBIZ with Ernst & Young as auditor

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

CorMedix Inc. changed its independent registered public accounting firm, appointing Ernst & Young LLP (EY) as auditor for the fiscal year ending December 31, 2026. The Audit Committee dismissed CBIZ CPAs P.C. on June 25, 2026. CBIZ’s report on the 2025 financial statements contained no adverse opinion or qualification. The only reportable event during CBIZ’s tenure was a previously disclosed material weakness in internal control over financial reporting related to timely review of significant, non-routine transactions, first reported in the 2025 Form 10-K filed March 5, 2026. CBIZ has been authorized to respond fully to EY about this matter and has provided a letter to the SEC agreeing or commenting on the company’s statements.

Positive

  • None.

Negative

  • None.
Item 4.01 Changes in Registrant's Certifying Accountant Governance
The company changed its independent auditing firm, which may involve disagreements on accounting matters.
Auditor dismissal date June 25, 2026 Date Audit Committee dismissed CBIZ CPAs P.C.
New auditor fiscal year Year ending December 31, 2026 Engagement period for Ernst & Young LLP
Prior year-end audited by CBIZ December 31, 2025 Fiscal year covered by CBIZ’s report
10-K filing date with weakness March 5, 2026 Date 2025 Form 10-K reporting material weakness was filed
CBIZ SEC letter date July 1, 2026 Date of CBIZ CPAs’ letter filed as Exhibit 16.1
independent registered public accounting firm financial
"approved the decision to change its independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
material weakness financial
"The material weakness in the Company’s internal control over financial reporting"
A material weakness is a significant flaw in the systems and checks a company uses to ensure its financial reports are accurate, meaning errors or fraud could happen and not be caught. For investors it matters because it raises the risk that reported results are unreliable—similar to finding a hole in a ship’s hull—potentially leading to corrected financials, regulatory action, reduced trust, and negative effects on stock value and borrowing costs.
internal control over financial reporting financial
"material weakness in the Company’s internal control over financial reporting"
Internal control over financial reporting is a company’s system of procedures and checks designed to make sure its financial statements are accurate and complete, like a set of guardrails and verification steps that catch mistakes or fraud before numbers are published. Investors care because strong controls make reported results more trustworthy, lower the risk of surprise restatements or regulatory problems, and give greater confidence when valuing the company or comparing it to peers.
reportable events regulatory
"no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K), except for"
Reportable events are significant incidents or changes a company is legally required to disclose to regulators and the public, such as major safety problems, legal actions, financial irregularities, or management changes. They matter to investors because these events can alter a company’s risk profile or future performance, much like a dashboard warning light signals a problem that could affect a car’s safety or reliability. Timely disclosure helps investors make informed decisions and maintain market fairness.
Regulation S-K regulatory
"as defined in Item 304(a)(1)(iv) of Regulation S-K"
A set of U.S. Securities and Exchange Commission rules that tell public companies which narrative and qualitative details must be disclosed in filings, such as risk factors, management discussion, executive pay, legal proceedings and business description. Think of it as a standardized checklist or blueprint that ensures investors get the same types of background information from every company so they can compare risks, management quality and strategy before making investment decisions.
Audit Committee financial
"the Audit Committee of the Board of Directors of CorMedix Inc."
A company's audit committee is a small group of board members who act like independent inspectors for the firm's finances, overseeing how financial reports are prepared, monitoring internal controls, and managing the relationship with external auditors. Investors care because a strong audit committee reduces the risk of accounting errors, fraud, or misleading statements, making financial statements more trustworthy and helping protect shareholder value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
FALSE0001410098false000141009800014100982026-06-252026-06-25

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 25, 2026
CORMEDIX INC.
(Exact name of registrant as specified in its charter)
Delaware001-3467320-5894890
(State or other jurisdiction of
incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
389 Interpace Parkway, Suite 450
Parsippany, NJ
07054
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (908) 517-9500

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2, below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, $0.001 par valueCRMDNasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 4.01 Changes in Registrant’s Certifying Accountant.
(a) Dismissal of Independent Registered Public Accounting Firm

On June 25, 2026, the Audit Committee of the Board of Directors of CorMedix Inc. (the “Company”) approved the decision to change its independent registered public accounting firm and dismissed CBIZ CPAs P.C. (“CBIZ CPAs ”) as the Company’s independent registered public accounting firm.

As previously disclosed in a Current Report on Form 8-K filed on April 22, 2025, on April 17, 2025 Marcum LLP was dismissed, and CBIZ CPAs was appointed, as the Company’s independent registered public accounting firm as a result of the acquisition by CBIZ CPAs of the Marcum LLP attest business. The report of CBIZ CPAs on the Company’s financial statements as of and for the fiscal year ended December 31, 2025 did not contain any adverse opinion or disclaimer of opinion, nor were such reports qualified or modified as to uncertainty, audit scope, or accounting principles.

From April 17, 2025 and through June 25, 2026, there were (i) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation S-K) with CBIZ CPAs on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of CBIZ CPAs, would have caused CBIZ CPAs to make reference thereto in connection with CBIZ CPAs’ reports, and (ii) no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S-K), except for:

• The material weakness in the Company’s internal control over financial reporting as initially reported in Item 9A of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed with the Securities and Exchange Commission (the “SEC”) on March 5, 2026, related to the operational effectiveness of an internal control to ensure adequate and timely review of significant, non-routine transactions.

The above reportable event was discussed between the Audit Committee and CBIZ CPAs. CBIZ CPAs has been authorized by the Company to respond fully to the inquiries of Ernst & Young LLP (“EY”), the successor independent registered public accounting firm, concerning this reportable event.

The Company provided CBIZ CPAs with a copy of this Current Report on Form 8-K prior to its filing with the Securities and Exchange Commission (“SEC”) and requested that CBIZ CPAs furnish it with a letter addressed to the SEC stating whether or not it agrees with the above statements in this Item 4.01(a). A copy of CBIZ CPAs’ letter, dated July 1, 2026, is filed as Exhibit 16.1 to this Current Report on Form 8-K.

(b) Appointment of New Independent Registered Public Accounting Firm

On June 25, 2026, the Audit Committee approved the appointment of EY as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2026. During the fiscal years ended December 31, 2025 and 2024 and the subsequent interim period through June 25, 2026, neither the Company nor anyone acting on its behalf consulted with EY regarding any of the matters referred to in Item 304(a)(2)(i) or (ii) of Regulation S-K.


(d) Exhibits
Exhibit No. Description
16.1
Letter of CBIZ CPAs CPAs P.C. dated July 1, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
1

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CORMEDIX INC.
7/1/2026By:/s/ Susan Blum
Name:Susan Blum
Title:Executive Vice President and Chief Financial Officer (Principal Financial and Accounting Officer)
2

Source: View Original Filing on SEC EDGAR

FAQ

What auditor change did CorMedix (CRMD) disclose in this 8-K?

CorMedix Inc. disclosed that its Audit Committee dismissed CBIZ CPAs P.C. and appointed Ernst & Young LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2026. The change was approved on June 25, 2026.

Why was CBIZ CPAs P.C. dismissed by CorMedix (CRMD)?

The filing states only that the Audit Committee approved a decision to change the independent registered public accounting firm, dismissing CBIZ CPAs P.C.. It does not cite disagreements on accounting, disclosure, or audit scope that would have required reference in CBIZ’s audit reports.

Did CorMedix (CRMD) report any disagreements with CBIZ CPAs?

CorMedix reports that from April 17, 2025 through June 25, 2026, there were no disagreements with CBIZ CPAs on accounting principles, financial statement disclosure, or audit scope or procedures, as defined in Item 304(a)(1)(iv) of Regulation S-K.

What material weakness did CorMedix (CRMD) disclose in internal controls?

The company disclosed a material weakness in internal control over financial reporting related to the operational effectiveness of an internal control to ensure adequate and timely review of significant, non-routine transactions. This weakness was first reported in its Form 10-K for the year ended December 31, 2025.

How did CorMedix (CRMD) and CBIZ handle the reported control weakness?

The material weakness was discussed between the Audit Committee and CBIZ CPAs. CorMedix authorized CBIZ to respond fully to inquiries from Ernst & Young LLP about this matter, and CBIZ provided a letter to the SEC addressing the company’s statements.

What role will Ernst & Young LLP play for CorMedix (CRMD)?

Ernst & Young LLP (EY) has been appointed as CorMedix’s new independent registered public accounting firm for the fiscal year ending December 31, 2026. The company states it did not consult EY on the specific accounting matters referenced in Item 304(a)(2) of Regulation S-K.

Filing Exhibits & Attachments

4 documents

Other Documents